B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: A European Hematology Association Survey (EPICOVIDEHA)
Maria Stefania Infante
(1)
,
Jon Salmanton-García
(2, 3)
,
Ana Fernández-Cruz
(4)
,
Francesco Marchesi
(5)
,
Ozren Jaksic
(6)
,
Barbora Weinbergerová
(7)
,
Caroline Besson
(8)
,
Rafael F Duarte
(4)
,
Federico Itri
(9)
,
Toni Valković
(10, 11)
,
Tomáš Szotkovski
(12)
,
Alessandro Busca
(13)
,
Anna Guidetti
(14)
,
Andreas Glenthøj
(15)
,
Graham P Collins
(16)
,
Valentina Bonuomo
(17)
,
Uluhan Sili
(18)
,
Guldane Cengiz Seval
(19)
,
Marina Machado
(20)
,
Raul Cordoba
(21)
,
Ola Blennow
(18)
,
Ghaith Abu-Zeinah
(22)
,
Sylvain Lamure
,
Sylvain Lamure
(23, 24)
,
Austin Kulasekararaj
(25)
,
Iker Falces-Romero
(26)
,
Chiara Cattaneo
(27)
,
Jaap van Doesum
(28)
,
Klára Piukovics
(29)
,
Ali S Omrani
(30)
,
Gabriele Magliano
(31)
,
Marie-Pierre Ledoux
(32)
,
Cristina de Ramon
(33, 34)
,
Alba Cabirta
(35, 36)
,
Luisa Verga
(37, 38)
,
Alberto López-García
(21)
,
Maria Gomes da Silva
(39)
,
Zlate Stojanoski
(40)
,
Stef Meers
(41)
,
Tobias Lahmer
(42)
,
Sonia Martín-Pérez
(43)
,
Julio Dávila-Vals
(43)
,
Jens van Praet
(44)
,
Michail Samarkos
(45)
,
Yavuz M Bilgin
(46)
,
Linda Katharina Karlsson
(15)
,
Josip Batinić
(47)
,
Anna Nordlander
(18)
,
Martin Schönlein
(48)
,
Martin Hoenigl
(49, 50, 51)
,
Zdeněk Ráčil
(52)
,
Miloš Mladenović
(53)
,
Michaela Hanakova
(52)
,
Giovanni Paolo Maria Zambrotta
(54, 38)
,
Nick de Jonge
(55)
,
Tatjana Adžić-Vukičević
(53)
,
Raquel Nunes-Rodrigues
(39)
,
Lucia Prezioso
(56)
,
Milan Navrátil
(57)
,
Monia Marchetti
(58)
,
Annarosa Cuccaro
(59)
,
Maria Calbacho
(60)
,
Antonio Giordano
(61, 62)
,
Oliver A Cornely
(2, 63, 64, 65, 66)
,
José-Ángel Hernández-Rivas
(1)
,
Livio Pagano
(62)
1
Hospital Universitario Infanta Leonor [Madrid]
2 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD)
3 Universität zu Köln = University of Cologne
4 Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain]
5 IRE - IFO - Istituto Nazionale Tumori Regina Elena [Roma]
6 Dubrava University Hospital
7 MUNI - Masaryk University [Brno]
8 CHV - Centre Hospitalier de Versailles André Mignot
9 SLGUH Orbassano - San Luigi Gonzaga University Hospital [Turin, Italy]
10 University Hospital Rijeka
11 CROHEM - Croatian Cooperative Group for Hematological Diseases
12 University Hospital Olomouc
13 AOU Città della Salute e della Scienza Hospital
14 IRCCS Istituto Nazionale dei Tumori [Milano]
15 Rigshospitalet [Copenhagen]
16 Churchill Hospital Oxford Centre for Haematology
17 UNIVR - Università degli studi di Verona = University of Verona
18 Marmara University [Kadıköy - İstanbul]
19 Ankara University School of Medicine [Turkey]
20 Hospital General Universitario "Gregorio Marañón" [Madrid]
21 FJD - Hospital Universitario Fundación Jiménez Díaz [Madrid]
22 Weill Cornell Medicine [Cornell University]
23 CHU Montpellier = Montpellier University Hospital
24 IGMM - Institut de Génétique Moléculaire de Montpellier
25 KCH - King's College Hospital
26 La Paz University Hospital
27 ASST Spedali Civili of Brescia,
28 UMCG - University Medical Center Groningen [Groningen]
29 University of Szeged [Szeged]
30 Hamad Medical Corporation [Doha, Qatar]
31 ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia]
32 ICANS - Institut de Cancérologie de Strasbourg Europe
33 Hospital Clinico Universitario de Salamanca [España] = University Hospital of Salamanca [Spain]
34 IBSAL - Instituto de Investigación Biomédica de Salamanca
35 VHIO - Vall d'Hebron Institute of Oncology [Barcelone]
36 UAB - Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona
37 Azienda Ospedaliera San Gerardo
38 UNIMIB - Università degli Studi di Milano-Bicocca = University of Milano-Bicocca
39 IPO Porto - Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto
40 UCH - University Clinic of Hematology [Skopje, Republic of North Macedonia]
41 AZ Klina
42 MRI TUM - Klinikum rechts der Isar
43 Hospital Nuestra Señora de Sonsoles
44 Department of ENT surgery, AZ Sint Jan Brugge Oostende
45 Laikon General Hospital
46 ADRZ - Admiral de Ruyter Medical Center
47 University Hospital Centre Zagreb
48 UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg]
49 UC San Diego Health
50 La Jolla Institute for Immunology [La Jolla, CA, États-Unis]
51 Medical University of Graz = Medizinische Universität Graz
52 Institute of Hematology and Blood Transfusion [Prague, Czech Republic]
53 COVID Hospital "Batajnica" (Belgrade)
54 SGH - San Gerardo Hospital [Monza, Italy]
55 Amsterdam UMC - Amsterdam University Medical Centers
56 UO Ematologia/CTMO
57 University Hospital Ostrava
58 Ospedale SS Antonio e Biagio e Cesare Arrigo
59 AUTNO - Azienda Usl Toscana nord ovest
60 Hospital Universitario 12 de Octubre [Madrid]
61 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
62 Unicatt - Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma]
63 University Hospital of Cologne [Cologne]
64 ZKS - Centre for Clinical Studies
65 CMMC - Center for Molecular Medicine [Cologne]
66 DZIF - German Center for Infection Research - Partner Site Bonn-Cologne
2 Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD)
3 Universität zu Köln = University of Cologne
4 Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain]
5 IRE - IFO - Istituto Nazionale Tumori Regina Elena [Roma]
6 Dubrava University Hospital
7 MUNI - Masaryk University [Brno]
8 CHV - Centre Hospitalier de Versailles André Mignot
9 SLGUH Orbassano - San Luigi Gonzaga University Hospital [Turin, Italy]
10 University Hospital Rijeka
11 CROHEM - Croatian Cooperative Group for Hematological Diseases
12 University Hospital Olomouc
13 AOU Città della Salute e della Scienza Hospital
14 IRCCS Istituto Nazionale dei Tumori [Milano]
15 Rigshospitalet [Copenhagen]
16 Churchill Hospital Oxford Centre for Haematology
17 UNIVR - Università degli studi di Verona = University of Verona
18 Marmara University [Kadıköy - İstanbul]
19 Ankara University School of Medicine [Turkey]
20 Hospital General Universitario "Gregorio Marañón" [Madrid]
21 FJD - Hospital Universitario Fundación Jiménez Díaz [Madrid]
22 Weill Cornell Medicine [Cornell University]
23 CHU Montpellier = Montpellier University Hospital
24 IGMM - Institut de Génétique Moléculaire de Montpellier
25 KCH - King's College Hospital
26 La Paz University Hospital
27 ASST Spedali Civili of Brescia,
28 UMCG - University Medical Center Groningen [Groningen]
29 University of Szeged [Szeged]
30 Hamad Medical Corporation [Doha, Qatar]
31 ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia]
32 ICANS - Institut de Cancérologie de Strasbourg Europe
33 Hospital Clinico Universitario de Salamanca [España] = University Hospital of Salamanca [Spain]
34 IBSAL - Instituto de Investigación Biomédica de Salamanca
35 VHIO - Vall d'Hebron Institute of Oncology [Barcelone]
36 UAB - Universitat Autònoma de Barcelona = Autonomous University of Barcelona = Universidad Autónoma de Barcelona
37 Azienda Ospedaliera San Gerardo
38 UNIMIB - Università degli Studi di Milano-Bicocca = University of Milano-Bicocca
39 IPO Porto - Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto
40 UCH - University Clinic of Hematology [Skopje, Republic of North Macedonia]
41 AZ Klina
42 MRI TUM - Klinikum rechts der Isar
43 Hospital Nuestra Señora de Sonsoles
44 Department of ENT surgery, AZ Sint Jan Brugge Oostende
45 Laikon General Hospital
46 ADRZ - Admiral de Ruyter Medical Center
47 University Hospital Centre Zagreb
48 UKE - Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg]
49 UC San Diego Health
50 La Jolla Institute for Immunology [La Jolla, CA, États-Unis]
51 Medical University of Graz = Medizinische Universität Graz
52 Institute of Hematology and Blood Transfusion [Prague, Czech Republic]
53 COVID Hospital "Batajnica" (Belgrade)
54 SGH - San Gerardo Hospital [Monza, Italy]
55 Amsterdam UMC - Amsterdam University Medical Centers
56 UO Ematologia/CTMO
57 University Hospital Ostrava
58 Ospedale SS Antonio e Biagio e Cesare Arrigo
59 AUTNO - Azienda Usl Toscana nord ovest
60 Hospital Universitario 12 de Octubre [Madrid]
61 Fondazione Policlinico Universitario Agostino Gemelli IRCCS
62 Unicatt - Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma]
63 University Hospital of Cologne [Cologne]
64 ZKS - Centre for Clinical Studies
65 CMMC - Center for Molecular Medicine [Cologne]
66 DZIF - German Center for Infection Research - Partner Site Bonn-Cologne
Sylvain Lamure
- Fonction : Auteur
Sylvain Lamure
- Fonction : Auteur
- PersonId : 745531
- IdHAL : sylvain-lamure
- ORCID : 0000-0001-5980-305X
Oliver A Cornely
- Fonction : Auteur
Résumé
Patients with lymphoproliferative diseases (LPD) are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Here, we describe and analyze the outcome of 366 adult patients with chronic lymphocytic leukemia (CLL) or non-Hodgkin Lymphoma (NHL) treated with targeted drugs and laboratory-confirmed COVID-19 diagnosed between February 2020 and January 2022. Median follow-up was 70.5 days (IQR 0-609). Most used targeted drugs were Bruton-kinase inhibitors (BKIs) (N= 201, 55%), anti-CD20 other than rituximab (N=61, 16%), BCL2 inhibitors (N=33, 9%) and lenalidomide (N=28, 8%).Only 16.2% of the patients were vaccinated with 2 or more doses of vaccine at the onset of COVID-19. Mortality was 24% (89/366) on day 30 and 36%(134/366) on the last day of follow-up. Age >75 years (p<0.001, HR 1.036), active malignancy (p<0.001, HR 2.215), severe COVID-19 (p=0.017, HR 2.270) and admission to ICU (p<0.001, HR 5.751) were risk factors for mortality at last day of follow up. There was no difference in OS rates in NHL vs CLL patients (p=0.306), nor in patients treated with or without BKIs (p=0.151). Mortality in ICU was 66% (CLL 61%, NHL 76%). Overall mortality rate decreased according to vaccination status, being 39% in unvaccinated patients, 32% and 26% in those having received one or two doses, respectively, and 20% in patients with a booster dose (p=0.245). Overall mortality rate dropped from 41% during the first semester of 2020 to 25% at the last semester of 2021. These results show increased severity and mortality from COVID-19 in LPDs patients treated with targeted drugs.
| Origine | Fichiers éditeurs autorisés sur une archive ouverte |
|---|---|
| Licence |
